biosensis fine bioscience tools - antibodies, elisa kits, proteins, toxins and peptides An Australia-US partnershipPhone: 1800 605 5127 in the US, or +61 8 8352 7711 for international enquiries to Australia.
HomeAbout BiosensisBiosensis distributorsResourcesHelp deskordering from BiosensisContact usFlyers
 


Technical Notes
 
View our tech notes
 
 
Follow us...
 
Google+ Follow us on Twitter

Find us on Facebook

Sign up for Biosensis newsletters
Visit our newsletter archive
 
 

Favipiravir (25 mg)

$247.00USD


Catalogue No. PE-1853-25
Description Pharmacology: Favipiravir is an inhibitor of influenza viruses A, B, and C (IC50s: A = 0.03-0.20 μg/mL H1N1; 0.01-0.30 H2N2; 0.08-0.48 H3N2; 0.14-0.15 H4N2; 0.24-1.60 H7N2;0.20-0.82 H5N1; 0.35 H1N2; B = 0.04-0.09 μg/mL; C = 0.03-0.06 μg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir (1-3). It displays no cytotoxicity in a variety of cell lines. Selectively inhibits viral RNA-dependent RNA polymerase (4). Displays activity against other viruses including arena, phlebo, hanta, flavi, entero, alpla, respiratory syncytial, and noroviruses (5). In clinical trials for treatment of SARSCoV-2 (6,7). PubChem CID: 492405

Product is sold for research use only. Not for human therapeutic use or for medicinal purposes.
Batch No. See product label.
Unit size 25 mg
Other Names 6-Fluoro-3-hydroxypyrazine-2-carboxamide; CAS 259793-96-9; T-705
Molecular Weight 157.1 g/mol Molecular Formula: C5H4FN3O2
Compound Name 6-Fluoro-3-hydroxypyrazine-2-carboxamide
Purity >99% (HPLC); NMR (Conforms)
Biol. activity Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes. Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
Applications Biochemical inhibition.
Appearance Dry, off-white powder.
Reconstitution Soluble in DMSO. May be dissolved in DMSO up to 30 mg/mL, or water up to 12 mg/mL.
Storage Store desiccated as supplied at -20C for up to 2 years. Store solutions at -20C for up to 1 month. Prevent multiple freeze-thaw cycles.
Expiry Date See storage conditions.
General References 1. Y Furuta et al. Antimicrob. Agents Chemother. 2002 46:977
2. K Takahashi et al. Antivir. Chem. Chemother. 2003 14:235
3. K Sleeman et al. Antimicrob. Agents Chemother. 2010 54:2517
4. Y Furuta et al. Antimicrob. Agents Chemother. 2005 49:981
5. Y Furuta et al. Antiviral Res. 2013 100:446
6. L Dong et al. Drug Discov.Ther. 2020 14:58
7. YF Tu et al. Int. J. Mol. Sci. 2020 21:E2657
Images (click to zoom)
Favipiravir (25 mg)

PDF Data Sheet

Click to download the data sheet - Click to download the Data Sheet

MSDS

Click to download the MSDS - Click to download the MSDS

Offices in the USA and Australia
My Ice Bucket  
 
0 items
 
 
Currencies
 
  
 
 
Email This Page
 
 
Tell someone you know about this product.
 
 
We Accept PayPal
 
You can use secured services of paypal to send us money via our email account MODULE_PAYMENT_PAYPAL_IPN_IDYou can use secured services of paypal to send us money via our email account MODULE_PAYMENT_PAYPAL_IPN_IDYou can use secured services of paypal to send us money via our email account MODULE_PAYMENT_PAYPAL_IPN_ID
Click to make a payment


Official PayPal Seal